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Abstract
Introduction
Little is known about medication use among women with eating disorders in relation to
pregnancy.
Aims
To explore patterns of and associations between use of psychotropic, gastrointestinal and
analgesic medications and eating disorders in the period before, during and after
pregnancy.
Method
This study is based on the Norwegian Mother and Child Cohort Study (MoBa). A total of
62,019 women, enrolled at approximately 17 weeks' gestation, had valid data from the Nor-
wegian Medical Birth Registry and completed three MoBa questionnaires. The question-
naires provided diagnostic information on broadly defined anorexia nervosa (AN), bulimia
nervosa (BN), binge eating disorder (BED) and recurrent self-induced purging in the
absence of binge eating (EDNOS-P), along with self-reported use of medication six months
before, during, and 0–6 months after pregnancy.
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Results
The prevalence of eating disorder subtypes before and/or during pregnancy was: 0.09% AN
(n = 54), 0.94% BN (n = 585), 0.10% EDNOS-P (n = 61) and 5.00% BED (n = 3104). The
highest over-time prevalence of psychotropic use was within the AN (3.7–22.2%) and
EDNOS-P (3.3–9.8%) groups. Compared to controls, BN was directly associated with inci-
dent use of psychotropics in pregnancy (adjusted RR: 2.25, 99% CI: 1.17–4.32). Having AN
(adjusted RR: 5.11, 99% CI: 1.53–17.01) or EDNOS-P (adjusted RR: 6.77, 99% CI: 1.41–
32.53) was directly associated with use of anxiolytics/sedatives postpartum. The estimates
of use of analgesics (BED) and laxatives (all eating disorders subtypes) were high at all
time periods investigated.
Conclusions
Use of psychotropic, gastrointestinal, and analgesic medications is extensive among
women with eating disorders in the period around pregnancy. Female patients with eating
disorders should receive evidence-based counseling about the risk of medication exposure
versus the risk of untreated psychiatric illness during pregnancy and postpartum.
Introduction
Eating disorders are serious mental illnesses primarily affecting women of childbearing age. It
is estimated that 0.9%, 1.5%, and 3.5% of the female population experience anorexia nervosa
(AN), bulimia nervosa (BN), or binge eating disorder (BED), respectively, over the life time
[1]. An active or past eating disorder does not preclude a woman from getting pregnant. Even
women with AN, despite the high prevalence of menstrual disturbances (up to 90%), may
become pregnant during an intermittent phase of regular ovulation, or during the first ovula-
tion after a period of amenorrhea [2]. The fertility rate and parity among women with eating
disorders is comparable to that observed in the general population, although women with BN
seem to undergo fertility treatments more frequently than healthy controls [3–5]. On the other
hand, pregnancy is often unplanned among women suffering from AN [6].
During pregnancy, up to 7.5% of women may meet the diagnostic criteria for an eating dis-
order [7]. Eating disorders can negatively affect pregnancy outcome and not least maternal
health during pregnancy and postpartum. Indeed, women presenting eating disorder symp-
toms during pregnancy are more likely than women with no psychiatric illness to have a proba-
ble depressive and/or anxiety disorder during pregnancy and the postpartum period, and to
have greater worries over gestational weight gain [8–11]. Compared to healthy controls, having
BN or BED confers an increased risk of induced abortions and miscarriages, respectively, and
the latter eating disorder subtype may also increase the risk of having higher birth weight and
large for gestational age infants [12,13]. Maternal AN has been found to be associated with an
increased risk of miscarriage, low birth weight infants, suspect fetal distress and perinatal death
[3,14–16]; however it is still not clear whether this eating disorder may also increase the risk of
prematurity [12,15,16].
Few clinical trials have tested pharmacotherapy options for treatment of patients with eating
disorders. Although there is no evidence supporting general use of antidepressants or antipsy-
chotics for the treatment of AN, selective serotonin reuptake inhibitor (SSRI) antidepressants
seem to moderately reduce the symptoms of BN and BED, but exert little effect on full recovery
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[17–21]. Previous research in clinical settings has shown that 13% and 49% of women with AN
use antipsychotics an antidepressants, respectively [22]. Nevertheless, little is known about the
extent of use of psychotropics in a population-based setting.
The use of medication in women with eating disorders has as far as we know not been
explored in relation to pregnancy. Inadequate evidence-based counseling about medication
safety in pregnancy and negative information framing may led women to discontinue needed
medication once pregnant [23]. However, since pharmacotherapy with psychotropics might
reduce pregnancy-related exacerbation of eating disorder symptoms such as dieting or vomit-
ing, their effect would probably be beneficial for both mother and fetus rather than detrimental.
Since extreme dieting, compensatory behaviors, or psychiatric comorbidity among patients
with eating disorders are associated with several painful conditions, including gastrointestinal
complaints [24,25], a comprehensive understanding of medication use beyond psychotropics
including analgesics and gastrointestinal medication in women with eating disorders, is essen-
tial to ensure maternal-fetal health.
Thus, this study investigated patterns of use of psychotropic, analgesic, and gastrointestinal
medications before, during, and after pregnancy across eating disorder subtypes, and explored
the relationship between eating disorders and use of these specific medications during preg-
nancy and the postpartum, including whether there was a direct association between eating dis-
orders and medication use or whether the association was indirect, e.g. via an underlying
maternal depression and anxiety. We hypothesized a higher extent of medication use in the
pregnancy and postpartum periods among women with eating disorders compared to healthy
controls.
Materials and Methods
Study population and data collection
This study is based on the Norwegian Mother and Child Cohort Study (MoBa) and on records
in the Medical Birth Registry of Norway (MBRN). MoBa is a prospective population-based
pregnancy cohort study conducted by the Norwegian Institute of Public Health [26].
Participants were recruited from all over Norway from 1999–2008. The women consented
to participation in 40.6% of the pregnancies [27]. The cohort now includes 114,500 children,
95,200 mothers and 75,200 fathers. Participants were recruited through a postal invitation in
connection with a routine ultrasound examination offered to all pregnant women in Norway at
17–18 weeks of gestation. The current study is based on version 7 of the quality-assured data
files released for research including women who delivered between 1999 and 2009. Informed
consent was obtained from each participant. The study was approved by The Regional Com-
mittee for Medical Research Ethics and the Norwegian Data Inspectorate.
The MBRN is based on compulsory notification of all live births, stillbirths and induced
abortions and includes information on pregnancy, delivery and neonatal health [28]. Data
fromMoBa was linked to the MBRN via the women’s personal identification number. The
analysis population for this study included women who had a record in MBRN, and had
answered three self-administered MoBa questionnaires [29]. The first (Q1) and third (Q3)
questionnaires were completed in gestational weeks 13–17 and 30, respectively; the fourth
questionnaire (Q4), concerning the period from gestational week 30 and onwards, was distrib-
uted when the infant was six months old [26,29]. Among those who agreed to participate in the
MoBa, the response rate was 95% for Q1, 92% for Q3, and 87% for Q4 [26]. The exclusion cri-
teria and flow-chart to achieve the final population analysis are outlined in Fig 1.
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Measures
Eating disorder. Q1 included items on eating disorders and disordered eating behaviors
designed in accordance with the DSM-IV criteria [30]. These items have been utilized in several
publications based upon on MoBa data [12,31–36]. The same diagnostic questions have also
been used in previous studies on eating disorders in the Norwegian Twin Panel [37,38] and
they yielded prevalence estimates and comorbidity profiles similar to those seen in another
population-based sample [39]. In our analysis population, respondents completed Q1 at a
median of 17.1 weeks of gestation (interquartile range 16.0–18.6 weeks). Diagnostic algorithms
and hierarchies were constructed to define the presence of eating disorders in the six months
prior to pregnancy (retrospective assessment) and during pregnancy. Broadly defined AN was
defined as meeting the DSM-IV criteria for AN with the exception of amenorrhea and also hav-
ing a body mass index (BMI)<18.5 at the time of low weight. Our definition of AN is more in
accordance with DSM-5 since the amenorrhea criterion is eliminated. It was not possible to
classify AN during pregnancy because of the missing BMI criterion due to pregnancy-induced
weight gain. The other eating disorder categories included: broadly defined BN, endorsing at
least a weekly frequency of binge eating and either purging (vomiting, laxatives) or non-purg-
ing (exercise, fasting) compensatory behaviors; broadly defined BED, at least a weekly fre-
quency of binge eating in the absence of compensatory behaviors; and eating disorder not
otherwise specified-purging subtype (EDNOS-P), purging at least weekly in the absence of
binge eating. Questions for binge eating included both eating an unusually large amount of
food and the feeling of loss of control. The frequency criteria for binge eating and purging in
BN, BED, and EDNOS-P differed from the DSM-IV criteria but reflect the new DSM-5 criteria
(once a week instead of twice a week). As the symptom profile for many women changed in
the interval before pregnancy and during pregnancy, the following diagnostic hierarchy was
applied in order to assign only one diagnosis to each woman: AN, BN, EDNOS-P, BED, and no
eating disorder. All individuals who met AN criteria before pregnancy were categorized as AN
regardless of presentation during pregnancy. Those who met BN criteria either before or dur-
ing pregnancy and who did not meet AN criteria prior to pregnancy were categorized as BN. If
not classified as AN or BN, those who met criteria for EDNOS-P before or during pregnancy
and did not endorse binge eating at either time were categorized as EDNOS-P. Similarly, indi-
viduals who endorsed BED and did not endorse purging during or before pregnancy were
Fig 1. Flow-chart to achieve final study population.Conditions may overlap: excluded participants are not
mutually exclusive. *Weight either < 30 Kg or > 300 Kg; ^Height < 100 cm.
doi:10.1371/journal.pone.0133045.g001
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included in the BED group. Group assignment was made only when all responses were avail-
able to ensure accurate classification.
Outcome assessment
Self-reported information about type and timing of medication use was available from the
MoBa Q1, Q3 and Q4 [29]. Respondents were asked to report medication use for numerous
chronic, short-term, and pregnancy-related conditions as free entry text, along with the timing
of use (six months before pregnancy; first, second and third trimesters; and two time periods
postpartum [0–3 and 4–6 months after childbirth]). All medications recorded in Q1, Q3 and
Q4 were grouped according to the Anatomical Therapeutic Chemical (ATC)[40] codes, as out-
lined in S1 Table, into: psychotropics (i.e., antidepressants, antipsychotics, anxiolytics and sed-
atives), gastrointestinal medications (i.e., antacids, drugs for peptic ulcer and gastro-esophageal
reflux disease, laxatives), and analgesics (i.e., opioids, acetaminophen and other antipyretics,
and nonsteroidal anti-inflammatory drugs [NSAIDs]). When multiple drugs were used and
multiple timings checked, we considered the drugs to be used in all time periods. Our outcome
measures (dichotomous ‘Yes/No’) were: a) medication use at any time “during pregnancy”,
and “postpartum” separately, irrespective of the respondents’s medication use status in the
other time periods; b) incident use of medications “during pregnancy only” (i.e., women who
started taking the medication in pregnancy and were not using that medication neither before
nor after pregnancy) and “postpartum only” (i.e., women who started taking the medication
postpartum and were not using that medication neither before nor during pregnancy).
Assessment of maternal mental health
Symptoms of depression and anxiety during pregnancy and postpartum were measured via the
short versions of The Hopkins Symptom Checklist-25 (SCL-25): the Symptom Checklist-5
(SCL- 5) in Q1, and the Symptom Checklist-8 (SCL-8) in Q3 and Q4 [41,42]. The scale is con-
sidered a reliable screening instrument for depression and anxiety as defined by the ICD-10
[43]. Both SCL-5 and SCL-8 are highly correlated to the SCL-25 [42,44]. For each item of the
scales, a score from 1 to 4 can be assigned. Whenever the respondent completed more than a
half of the items, imputed values were generated on both instruments via utilization of the
estimation-maximization algorithm. Values were imputed for 1.4%, 5.4%, and 8.9% of the
study population in SCL-5 (Q1), SCL-8 (Q3), and SCL-8 (Q4), respectively. For all three instru-
ments, the mean score was separately computed. Presence of depressive and anxiety symptoms
during pregnancy was defined by a score greater than 2.0 in the SCL-5 and greater than 1.85
in the SCL-8 [41]. The mean scores for the SCL-5 in Q1 and the SCL-8 in Q3 were summed
(mean sum score) in order to measure symptoms of depression and anxiety throughout the
pregnancy.
Assessment of potential confounders and mediators
Maternal socio-demographics (i.e., age, educational level, socio-economic status, BMI at con-
ception, weight gain during pregnancy, weight decrease after childbirth, illnesses during preg-
nancy), life-style characteristics (i.e., smoking status until gestational week 30 and alcohol
intake during early pregnancy) and the degree of maternal depressive and anxiety symptoms
during pregnancy (mean sum score of SCL-5 and SCL-8) and postpartum (mean score of the
SCL-8) were all analyzed as potential confounders or mediators. Confounding and mediating
factors were identified with the aid of directed acyclic graphs (DAGs) using DAGitty version
2.2 (one DAG for each medication-outcome pair) [45]. Our assumptions were: eating disorder
status before and/or during pregnancy precedes maternal symptoms of depression and anxiety
Medication Use in Relation to Pregnancy and Eating Disorders
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during pregnancy; eating disorder status before and/or during pregnancy determines BMI at
conception. These assumptions applied to all the eating disorder subtypes.
Statistical analysis
All statistical analyses were performed by using the Statistical Package for the Social Sciences
(SPSS) version 22.0 (IBM SPSS Statistics). The Pearson chi-square or Fisher exact test, and the
Student's t-test were utilized to compare proportions and mean scores between independent
groups, respectively. Because of the numerous analyses, we undertook a conservative approach
and considered p-values of 0.01statistically significant.
The Generalized Estimating Equations (GEE) with a Poisson distribution [46] was used to
test differences in medication use across the eating disorder subtypes. In the first set of analyses
we explored medication use “during pregnancy” and “postpartum” separately. In the second
set, we assessed incident use of medications “during pregnancy only” and “postpartum only”.
In the two sets of analyses we carried out the following steps: we first computed crude relative
risks (RR) with 99% CI. Then, we entered in Model 1 the minimal sufficient adjustment set of
variables (i.e., age, socioeconomic, status and educational level for all medication groups) for
estimating the total association between eating disorders and the outcomes of interest. In a sen-
sitivity analysis we included BMI at conception as additional covariate in Model 1 (because of
the uncertainty in the direction of the association between BMI and eating disorders); however,
the observed results did not differ substantially from the main analyses. In Model 2 we entered
the set of confounders fromModel 1 plus additional covariates (e.g., maternal depressive and
anxiety symptoms, BMI, weight gain in pregnancy, alcohol use during early pregnancy and
smoking until gestational week 30) in order to estimate the direct association between eating
disorders and the outcomes of interest. Data are presented as crude and adjusted RR if there
were at least three cases of women with eating disorders exposed to the specific medication
groups.
Results
Population characteristics
A total of 62,019 women were included in this study (Fig 1). Those excluded from the analysis
because of missing eating disorder assessment (n = 5,934, 9.6%) were significantly older, had
less education, lower socio-economic status, and higher BMI at conception than those
included. Women completing Q1 but not Q3 (i.e., they were lost to follow-up at gestational
week 30) were more likely than women completing both Q1 and Q3 to have symptoms of
depression and anxiety around gestational week 17 (11.0% vs. 6.9%, respectively; p<0.001).
Similarly, the prevalence of eating disorders was significantly higher (p<0.001) among women
who were lost to follow-up than individuals remaining in the study (AN: 0.2% vs. 0.1%), BN
(1.5% vs. 1.0%), EDNOS-P (0.3% vs. 0.1%), and BED (6.4% vs. 5.1%). The analysis of attrition
bias in relation to women lost to follow-up at six months postpartum showed that women com-
pleting Q1 and Q3 but not Q4 had a significantly higher burden of depressive symptoms
around gestational week 30 compared to women who did complete Q4 (10.7% vs. 6.7%, respec-
tively; p<0.001).
In our study population, the prevalence of eating disorder subtypes before and/or during
pregnancy was: 0.09% AN (n = 54), 0.94% BN (n = 585), 0.10% EDNOS-P (n = 61) and 5.00%
BED (n = 3,104). The remaining 93.87% did not present with any eating disorders (reference
group). Maternal socio-demographics, life-style factors, morbidities, and mental health charac-
teristics across the eating disorder subtypes are outlined in Table 1. Women within the AN,
BN, EDNOS-P, and BED groups more frequently had less education and lower socio-economic
Medication Use in Relation to Pregnancy and Eating Disorders
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Table 1. Maternal sociodemographics, morbidities andmental health across the eating disorder subtype (n = 62,019)†.
AN (n = 54) BN (n = 585) EDNOS-P (n = 61) BED (n = 3,104) No ED (n = 58,215)
Sociodemographics and life-style factors
Age (in years) (Mean ± sd) 26.8 ± 4.7* 29.5 ± 4.7‡ 28.0 ± 5.3* 30.1 ± 4.7 30.0 ± 4.5
BMI at conceptiona (Mean ± sd) 18.2 ± 0.6* 24.1 ± 4.3 23.7 ± 4.5 25.9 ± 5.1* 23.9 ± 4.1
Previous children (%)
No 37 (68.5) 324 (55.4) 39 (63.9) 1,517 (48.9)* 32,226 (55.4)
Yes 17 (31.5) 261 (44.6) 22 (36.1) 1,587 (51.1) 25,989 (44.6)
Marital status (%)
Married/cohabiting 52 (96.3) 540 (93.6)* 51 (85.0)* 2,958 (95.8)* 56,139 (96.9)
Others 2 (3.7) 37 (6.4) 9 (15.0) 130 (4.2) 1,822 (3.1)
Educational levelb (%)
Primary/secondary school 28 (57.1)* 244 (44.9)* 30 (50.0)‡ 1,292 (43.8)* 18,514 (33.5)
University/higher degree 21 (42.9) 299(55.1) 30 (50.0) 1,657 (56.2) 36,691 (66.5)
Minimum household income (%)
0–499,999 NOK ($0–77,999) 24 (46.2)* 114 (21.3)‡ 17 (32.1)‡ 632 (21.9)* 9,976 (18.3)
500–999,999 NOK ($78,000–155,999) 26 (50.0) 382 (71.4) 33 (62.3) 2,113 (73.1) 40,986 (75.3)
>1 million NOK ($156,000) 2 (3.8) 27 (5.0) 1 (1.9) 102 (3.5) 2,900 (5.3)
Unknown - 12 (2.2) 2 (3.8) 45 (1.6) 567 (1.0)
Smoking during pregnancyc (%)
No 42 (77.8) 457 (78.1) 49 (80.3) 2,456 (79.1) 45,567 (78.3)
Yes 3 (5.6) 47 (8.0) 6 (9.8) 249 (8.0) 4,710 (8.1)
Missing 9 (16.7) 81 (13.8) 6 (9.8) 399 (12.9) 7,938 (13.6)
Alcohol use during pregnancyd (%)
No 37 (68.5) 433 (74.0) 49 (80.3) 2,184 (70.4) 41,171 (70.7)
Yes 10 (18.5) 65 (11.1) 5 (8.2) 341 (11.1) 6,340 (10.9)
Missing 7 (13.0) 87 (14.9) 7 (11.5) 579 (18.7) 10,704 (18.4)
Illnesses during pregnancy (%)
Pelvic girdle/back/shoulder/other pains 45 (83.3) 483 (82.6)* 49 (80.3) 2,516 (81.1)* 42,937 (73.8)
Headache/migraine 25 (46.3) 261 (44.6)* 24 (39.3) 1,298 (41.8)* 19,937 (34.2)
Gastrointestinal disorderse 41 (75.9) 406 (69.4)* 43 (70.5) 2,159 (69.6)* 35,803 (61.5)
Mental health during pregnancy (%)
Depressive and anxiety symptomsf 12 (22.2)* 99 (16.9)* 8 (13.1)* 222 (7.2)* 1,255 (2.2)
Abbreviations: AN (anorexia nervosa), BN (bulimia nervosa), EDNOS-P (eating disorder not otherwise speciﬁed, purging type), BED (binge-eating
disorder), ED (eating disorder); BMI (body mass index); NOK (Norwegian Kroners).
aThe BMI is the weight in kilograms divided by the square of the height in meters: underweight: <18.5 kg/m2; normal weight: 18.5–24.9 kg/m2; overweight:
25.0–29.9 kg/m2; obese30 kg/m2.
bPrimary or secondary education: <10 years (primary) or 10–12 years (secondary) of education; University degree or higher: college or university
education.
cIndicates smoking until gestational week 30.
dIndicates alcohol use at the beginning of pregnancy, until gestational week 17.
eIncludes heartburn/reﬂux, duodenal/stomach ulcers, Crohn disease/ulcerative colitis and other gastrointestinal problems.
fIndicates scoring over the cut-off point at both gestational weeks 17 (5-items Hopkins symptoms checklist SCL-52) and 30 (8-items Hopkins symptoms
checklist SCL81.85).
†Numbers may not add up to total because of missing values (<5%). For the variables “smoking” and “alcohol use during pregnancy”, missing values were
up to 18% and a “missing category” was therefore created. The group “medication users with no ED” is the referent group for all analyses.
*Indicates p-value  0.001
‡Indicates p-value  0.01.
doi:10.1371/journal.pone.0133045.t001
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status than the reference group, and showed significantly higher rates of depressive and anxiety
symptoms throughout the pregnancy (Table 1).
Patterns of medication use
Fig 2 outlines the extent of psychotropic medication use overtime across the various eating dis-
order subtypes. Women with AN or EDNOS-P reported the highest rate of psychotropic medi-
cation use prior, during and after pregnancy. Use of psychotropics decreased during pregnancy
across all eating disorders compared to the period before conception; at 4–6 months postpar-
tum the AN and EDNOS-P groups were characterized by a significant increase in such use
(mainly anxiolytics and sedatives) (Fig 2 and S2 Table). The extent of use of the individual psy-
chotropic medications overtime, including regular use at all time periods and across the various
eating disorder subtypes is outlined in S2 Table. Overall, antidepressants comprised the medi-
cation class most widely used before, during, and after pregnancy.
S1 and S2 Figs outline the extent of use of gastrointestinal drugs and analgesics, respectively,
according to timing and across the eating disorder subtypes. Patterns of use for the individual
subgroups within gastrointestinal drugs and analgesics are shown in S3 and S4 Tables, respec-
tively. Women with any eating disorder were characterized by a high use of gastrointestinal
drugs during pregnancy (especially in the second and third trimester) and postpartum. Com-
pared to the reference group, all eating disorder subtypes were characterized by a higher rate of
laxative use at some point before, during, or after pregnancy (S3 Table).
Even though not always significantly different, use of analgesics was at almost all time points
higher among women with AN than the reference counterpart (S2 Fig). Women with BED
were characterized by a significantly higher use of any type of analgesics before, as well as dur-
ing and after pregnancy. Also, women with AN, BN or BED were more likely than the reference
group to use acetaminophen and other antipyretics at all time periods (S4 Table).
Association between eating disorders and medication use in pregnancy
Table 2 outlines the measure of association between the eating disorder subtypes and use of
specific medication groups during pregnancy. After adjusting for confounding factors (Model
1), women with AN, BN, EDNOS-P, and BED had a significant 5.6-, 4.0-, 3.6- and 1.7-fold
increased likelihood, respectively, to use psychotropics during pregnancy compared to the
Fig 2. Use of psychotropic medications before, during, and after pregnancy by type of eating
disorder†. Abbreviations: AN (anorexia nervosa), BN (bulimia nervosa), EDNOS-P (eating disorder not
otherwise specified, purging type), BED (binge-eating disorder), ED (eating disorder). †Psychotropic
medications include antidepressants, antipsychotics, anxiolytics and hypnotics and sedatives. *Indicates p-
value0.001; ‡Indicates p-value0.01.
doi:10.1371/journal.pone.0133045.g002
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reference group. Having BN was directly associated with use of psychotropics during preg-
nancy (1.8-fold magnitude) compared to not having any eating disorder. In a sub-analysis by
psychotropic subgroup, BED was found to be significantly directly associated with use of anti-
depressants during pregnancy (aRR: 1.45, 99% CI: 1.01–2.08), while BN had such effect on use
of anxiolytics and sedatives (aRR: 2.36, 99% CI: 1.26–4.41) compared to women with no eating
disorder. Only BN was significantly directly associated with incident use of psychotropics dur-
ing pregnancy (Model 2, aRR: 2.25, 99% CI: 1.17–4.32) compared to the reference group.
Women with BN or BED presented a significant 1.3- and 1.2-fold increased likelihood,
respectively, for taking gastrointestinal drugs during pregnancy compared to the reference
group (Model 1). However, only the EDNOS-P subtype was significantly directly associated
with this outcome (specifically for antacids and laxatives).
Compared to the reference group, having BN or BED were significantly associated with a
modest increased likelihood to use analgesics during pregnancy (Model 1, 11–19% increased
risk); however, none of the eating disorder subtypes was directly associated with this outcome
(Model 2). In the second set of analysis, women with BED presented a small significant likeli-
hood to be incident users of analgesics during pregnancy (Model 1, aRR: 1.14, 99% CI: 1.02–
1.28) compared to women with no eating disorder, although the association was not direct.
Association between eating disorders and medication use postpartum
Table 3 outlines the measure of association between the eating disorder subtypes and use of
specific medication groups postpartum. Women with AN, BN, EDNOS-P, and BED presented
Table 2. Measure of association between eating disorder subtypes andmedication use during pregnancy†.
Model 1* Model 2‡
Medication group Crude RR (99% CI) Adjusted RR (99% CI) Adjusted RR (99% CI)
Psychotropics
AN (n = 8) 6.08 (2.62–14.12) 5.63 (2.30–13.76) 1.98 (0.74–5.26)
BN (n = 61) 4.28 (3.11–5.89) 4.01 (2.84–5.66) 1.81 (1.21–2.71)
EDNOS-P (n = 7) 4.71 (1.88–11.80) 3.63 (1.21–10.85) 2.77 (0.95–8.08)
BED (n = 135) 1.78 (1.42–2.24) 1.71 (1.34–2.17) 1.09 (0.82–1.44)
No ED (n = 1,419) Referent Referent Referent
Gastrointestinal drugs
AN (n = 14) 1.13 (0.63–2.05) 1.30 (0.73–2.33) 1.52 (0.83–2.81)
BN (n = 167) 1.25 (1.05–1.48) 1.27 (1.06–1.52) 1.05 (0.84–1.30)
EDNOS-P (n = 20) 1.43 (0.89–2.30) 1.52 (0.93–2.49) 1.68 (1.09–2.59)
BED (n = 869) 1.23 (1.13–1.32) 1.19 (1.10–1.29) 1.01 (0.92–1.11)
No ED (n = 13,306) Referent Referent Referent
Analgesics
AN (n = 33) 1.24 (0.94–1.64) 1.42 (1.08–1.87) 1.27 (0.92–1.74)
BN (n = 338) 1.17 (1.07–1.28) 1.19 (1.08–1.31) 1.09 (0.98–1.21)
EDNOS-P (n = 35) 1.16 (0.88–1.55) 1.09 (0.78–1.53) 1.08 (0.75–1.57)
BED (n = 1,760) 1.15 (1.10–1.20) 1.11 (1.06–1.16) 1.03 (0.98–1.09)
No ED (n = 28,733) Referent Referent Referent
†Indicates medication use at any point during pregnancy, irrespective of the medication use status before or after pregnancy. The RR is computed when
there are at least 3 women exposed to the medication group of interest. Statistically signiﬁcant results are in bold.
*Model 1: Adjustment done for maternal age (as continuous variable), socioeconomic status and educational level (for all medication groups).
‡Model 2: Adjustment done for all covariates in Model 1 with addition of alcohol use during pregnancy, smoking during pregnancy, weight gain during
entire pregnancy (as continuous variable), BMI at conception (as continuous variable), depressive and anxiety symptoms throughout the pregnancy (as
continuous variable), pain ailments in pregnancy (for analgesics), and gastrointestinal disorders during pregnancy (for gastrointestinal drugs).
doi:10.1371/journal.pone.0133045.t002
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a significant 9.5-, 2.4-, 7.2- and 1.5-fold increased likelihood, respectively, to use psychotropics
in the period 0–6 months after delivery compared to the reference group (Model 1). Only the
EDNOS-P subtype was directly associated with this outcome (Model 2, 4.5-fold magnitude). In
the sub-analysis on type of psychotropics, AN and EDNOS-P were directly associated with an
increased likelihood of using anxiolytics/sedatives postpartum (Model 2, aRR: 5.11, 99% CI:
1.53–17.01; aRR: 6.77, 99% CI: 1.41–32.53, respectively) compared to women with no eating
disorders.
In Model 1, BN was significantly associated with a 1.8-fold increased likelihood to take gas-
trointestinal drugs postpartum compared to the reference group, and also showed a direct asso-
ciation with this outcome (Model 2, 1.6-fold magnitude). Women with BED, even though in a
modest magnitude, were more likely than the reference group to use analgesics postpartum
(1.2-fold increased risk); however, the association was not direct. No eating disorder was signif-
icantly associated with incident use of gastrointestinal drugs or analgesics postpartum.
Discussion
To our knowledge this is the first population-based study addressing the extent of medication
use among women with eating disorders in the period before, during, and after pregnancy. Sev-
eral of our findings are important for clinical practice. First, knowledge that use of psychotropic
medication, especially antidepressants, was common among women with any eating disorder
in the preconception period as well as during pregnancy and postpartum may assist clinicians
Table 3. Association between eating disorder subtypes and use of medication in the postpartum period†.
Model 1* Model 2‡
Medication group Crude RR (99% CI) Adjusted RR (99% CI) Adjusted RR (99% CI)
Psychotropics
AN (n = 7) 10.00 (4.02–24.94) 9.55 (3.58–25.48) 2.87 (0.91–9.08)
BN (n = 21) 2.77 (1.58–4.85) 2.44 (1.29–4.61) 0.93 (0.42–2.04)
EDNOS_P (n = 5) 6.33 (2.09–19.16) 7.16 (2.41–21.32) 4.47 (1.18–16.86)
BED (n = 62) 1.54 (1.10–2.16) 1.46 (1.02–2.10) 0.87 (0.56–1.35)
No ED (n = 754) Referent Referent Referent
Gastrointestinal drugs
AN (n = 5) 2.14 (0.71–6.42) 2.43 (0.83–7.18) 1.84 (0.43–7.78)
BN (n = 44) 1.74 (1.19–2.53) 1.82 (1.22–2.72) 1.63 (1.03–2.58)
EDNOS_P (n = 1) - - -
BED (n = 155) 1.16 (0.94–1.42) 1.19 (0.95–1.48) 1.17 (0.92–1.49)
No ED (n = 2,520) Referent Referent Referent
Analgesics
AN (n = 24) 1.19 (0.81–1.76) 1.20 (0.79–1.84) 1.16 (0.71–1.90)
BN (n = 237) 1.09 (0.95–1.24) 1.12 (0.98–1.29) 0.98 (0.84–1.15)
EDNOS_P (n = 20) 0.88 (0.55–1.41) 0.89 (0.53–1.49) 0.77 (0.40–1.48)
BED (n = 1,284) 1.11 (1.05–1.17) 1.12 (1.06–1.19) 1.06 (0.99–1.13)
No ED (n = 21,710) Referent Referent Referent
†Indicates medication use at any point in the period 0–6 months after delivery, irrespective of the medication use status before or during pregnancy. The
RR is computed when there are at least 3 women exposed to the medication group of interest. Statistically signiﬁcant results are in bold.
*Model 1: Adjustment done for maternal age (as continuous variable), socioeconomic status and educational level (for all medication groups).
‡Model 2: Adjustment done for all covariates in Model 1 with addition of weight decrease six months after delivery and breastfeeding status, depressive
and anxiety symptoms postpartum, and cesarean section (for analgesics).
doi:10.1371/journal.pone.0133045.t003
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when following-up or counseling female patients with eating disorders. Indeed, women with
eating disorders, either pregnant or planning a pregnancy, might be in special need of evi-
dence-based counseling about the benefit-risk ratio of gestational exposure to antidepressants
or other psychotropics, and that of untreated psychiatric illness. To date very little is known
about the distinct effects of treated versus untreated eating disorders on perinatal outcomes
[15,16]; however the detrimental impact of untreated maternal depression, which is highly
comorbid with eating disorders, on maternal-fetal health has been documented [47,48].
Second, women with AN or EDNOS-P presented the highest rate of psychotropic drug use
at all time periods investigated, which may be due to a high degree of psychiatric comorbidity
compared to the other groups of women. Women with AN were also those with the highest
extent of regular use (i.e., before, during and after pregnancy) of psychotropics (5.6%), which is
not completely unexpected since more than one out of five women with AN presented symp-
toms of depression and anxiety during pregnancy. Kaye et al.[49] showed in a double-blind
placebo-controlled trial that use of fluoxetine may be useful in improving outcome and pre-
venting relapse of patients with AN after weight restoration; since most women with AN are
weight restored during the course of the pregnancy, SSRI antidepressants, and in particular flu-
oxetine, may actually be more beneficial in this setting than before conception.
Third, women with EDNOS-P or AN had a 6.8- and 5.1-fold increased likelihood to use
pharmacotherapy with sedatives/anxiolytics in the postpartum period, even after cancelling
out the effect of factors such as weight decrease postpartum or depressive and anxiety symp-
toms. The substantial physical changes accompanying motherhood may represent a special
challenge for women with AN, being characterized by a profound fear of gaining weight and by
a distorted perception of body shape. Although about 50% of women with AN or EDNOS-P
have been shown to remit at 18 months postpartum [35], little is known about the course of
these disorders in the earlier postpartum period. Women with AN or EDNOS-P were found to
lose the gestational weight more quickly than controls over the first six months postpartum
[36], thus for these women a return to restrictive weight control behaviors and a worsening of
the anxiety symptomatology in the early postpartum period, requiring use of sedatives/anxio-
lytics, cannot be excluded.
Fourth, women with BED were characterized by an extensive use of analgesics before, dur-
ing and after pregnancy. In the multivariate analysis, though, BED was not directly associated
with analgesic use during pregnancy or postpartum, suggesting that other factors, namely
depressive and anxiety symptoms, pain ailments, BMI, weight change during pregnancy and
postpartum, rather than the binging behavior, might constitute the driving factors for using
analgesics.
Lastly, our study revealed that use of laxatives is high among women with any eating disor-
ders not only before pregnancy, but also during pregnancy and the postpartum, raising con-
cerns about the impact of this practice on their own health and that of their unborn children.
Our observed rates of use of psychotropics in the preconception period were lower than
those found in three previous studies among women with AN (53%), BED (18%), or all eating
disorders (96.7%)[22,50,51]; different recruitment strategies, that is, population-based recruit-
ment in the present study versus clinical research recruitment in others, country-specific thera-
peutic traditions and access to special care in different countries, could probably explain these
discrepancies. Factors such as pregnancy planning might have also deflated our estimates;
because of fear to harm the unborn child and elevated risk perception of medication exposure,
many women may discontinue their needed pharmacotherapy during pregnancy or when
attempting to conceive [52,53].
The lack of drug utilization studies among women with eating disorders during pregnancy
unfortunately precludes any comparison of our observed estimates of use of psychotropics
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with the existing literature. Yet, our crude estimates of use of antidepressants during pregnancy
among women with AN or EDNOS-P (AN: 13.0%, EDNOS-P: 8.2%) were not substantially dif-
ferent from those expected to occur among women with symptoms of depression in Norway
(about 9–13%)[54–56], although use was lower among women with BN or BED (BN: 5.6%,
BED: 2.8%). Indeed, the rates of depressive and anxiety symptomatology throughout preg-
nancy were significantly higher among women with any eating disorder than in the reference
group, ranging from 22.2% for AN to 7.2% for BED.
Although the association among eating disorders, alcohol consumption, and smoking is
well-established [28], this was not reflected in our pregnant sample. In fact, the crude estimates
of alcohol consumption during early pregnancy and smoking until the end of pregnancy
among women with eating disorders were not significantly different from those of the reference
group, although alcohol use was higher in the AN group. We also tested whether eating disor-
ders were directly associated with use of psychotropics, i.e. after adjusting for factors such as
maternal underlying depressive and anxiety symptomatology, weight gain and life-style factors,
including alcohol consumption during pregnancy. Then, only BN was directly associated with
use and incident use of psychotropics during pregnancy (1.8- and 2.3-fold, respectively) com-
pared to controls. Since antidepressants have shown some effects in reducing the binge-eating
and vomiting behaviors and fluoxetine is the only medication approved for treatment of BN
[57], this finding is expected. On the other hand, incident use of psychotropics might also rep-
resent a proxy of increased severity of a pre-existing or an incident case of BN. A previous
study [31] using the same data source found that the most common pattern for BN was remis-
sion or partial remission of symptoms from the pre-pregnancy period to early pregnancy, and
incident cases were rare. Given this scenario, we cannot exclude the possibility that pharmaco-
therapy with psychotropics might have contributed, at least to some extent, to remission of
symptoms among women with BN. Also, women with BN might have sought specialist care
and treatment once pregnant for the well-being of the fetus. Two previous studies have for
example shown that use of dietary supplements and nutritional intake during pregnancy were
similar among women with and without eating disorders [32,58], underscoring how these
women do their utmost to ensure the well-being of the developing fetus.
The extent of use of gastrointestinal medication observed in our study was high across all
the eating disorders; this finding may reflect a higher burden of gastrointestinal bothers during
pregnancy among women with eating disorders than in the healthy counterpart, but it raises
several concerns. In particular, women with BED were more often users of gastrointestinal
medications during pregnancy (antacids, laxatives, and drugs for gastroesophageal reflux dis-
ease [GERD]) and postpartum (drugs for GERD), though not prior to pregnancy, suggesting a
possible augmentation in severity or frequency of bingeing episodes during these periods, or
more intense pregnancy-related bothers in the gastrointestinal tract secondary to the binge.
Prior research using the MoBa cohort [31] has in fact shown that most women with BED expe-
rienced continuation of symptoms rather than remission during pregnancy compared to the
period before conception, and incident cases were not uncommon. In our multivariate model,
though, no direct associations between BED and use of gastrointestinal medications during
pregnancy and postpartum were found, implying the importance of indirect factors, namely
depressive and anxiety symptoms, weight gain or decrease, BMI and gastrointestinal concerns,
on these associations. EDNOS-P, on the other hand, was directly associated with use of gastro-
intestinal medications during pregnancy (mostly antacids), which may be secondary to regur-
gitation episodes or to an intensification of purging behavior (i.e., vomiting) during pregnancy
or, as shown by Torgersen et al., to the higher odds for these women to experience pregnancy-
related vomiting [59].
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In line with prior research showing an association between moderate to severe pain and eating
disorders [60], we found that use of analgesics before, during and after pregnancy was high across
all eating disorder subtypes. However, the multivariate analysis showed that when accounting for
factors such as depressive and anxiety symptoms, pain disorders and weight increase or decrease,
none of the eating disorders were directly associated with any analgesic use neither during nor
after pregnancy. The higher extent of use of NSAIDs in the third trimester among women with
AN, BN or EDNOS-P, however, deserves attention. Women should be advised against use of
NSAIDs in the third trimester since use of NSAIDs after week 32 has been associated with pre-
mature closure of the ductus arteriosus, oligohydramnios, and inhibition of labor [61].
Frequent follow-ups and support with treatment by a multidisciplinary team including
obstetricians, psychiatrists, and psychotherapists is of critical importance for women with eat-
ing disorders, especially in a vulnerable phase of life such as pregnancy and motherhood. The
high burden of psychiatric comorbidity and the extensive medication use among these women
deserves attention: clinicians are encouraged to query female patients about their medication-
taking behavior and provide evidence-based counseling about the risk of medication exposure
versus the risk of untreated psychiatric illness during pregnancy and postpartum. Sub-optimal
treatment of maternal psychiatric illness might lead to adverse outcomes such as a relapse of
the disorder, poor life-style or inadequate compliance with prenatal care, which are all harmful
factors for both mother and child. In moderate to severe cases of psychiatric illness pharmaco-
therapy may be necessary [62].
Strengths and Limitations of the Study
The MoBa study encompasses several strengths and limitations. Data collection was carried
out prospectively, avoiding the risk of recall bias. Use of medications in the period from gesta-
tional week 30 to childbirth was the only information collected retrospectively (in Q4), and
may therefore suffer of recall bias. However, the impact of misclassification of use of SSRIs (the
most common psychotropics in our sample) in late pregnancy on risk estimates was assessed
as minimal [63]. The collection of a vast array of health-related and sociodemographic infor-
mation enabled us to take into account several potential confounders and mediators. The
utilization of DAGs permitted a proper selection of confounding factors for the multivariate
models, thus diminishing the risk of over-adjustment. Symptoms of depression and anxiety
were measured at two time points in pregnancy and at six months postpartum via utilization of
validated instruments, i.e. the SCL-5 and SCL-8, which are reliable screening tools [41–44].
On the other hand, our study has several limitations that should be considered when inter-
preting the results. Assessment of broadly defined eating disorders was based on women´s self-
report, however the questions posed to the study participants were consistent with diagnostic
criteria [30]. Other psychometric instruments (e.g., the SCOFF questionnaire) could have been
used to identify individuals with eating disorders; however, the eating disorder hierarchy
employed in our study has been widely used [31,32,34–36]. Categorization based on diagnostic
interviews may have yielded better diagnostic information, although this approach was not fea-
sible in the context of the MoBa study given the large sample size. However, women may deny
the presence of stigmatized behaviors such as purging in face-to-face interviews [64]. It is plau-
sible that women with eating disorders who participated in MoBa may represent the healthier
end of the eating disorder severity spectrum because they had to be well enough to conceive
and participate overtime. Our prevalence estimate of AN was somewhat lower than the point
estimate reported in another study in pregnancy (0.1% vs. 0.5%, respectively). Such discrep-
ancy could be ascribed, at least in part, to the different diagnostic criteria utilized. In the present
study, the mean BMI at conception among women with AN may be an indicator of mild
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anorexic symptomatology; indeed, women with severe anorexia are most likely not well enough
to conceive and participate in a population-based research study. MoBa is a population-based
study, and therefore the BMI among women with broadly defined AN is expected to be higher
than the BMI expected in a clinical sample of patients with AN. Nonetheless, the gradient of
severity of eating disorders in participants included in clinical versus population-based studies
is not unexpected given the well-documented differences in severity and comorbidity across
population- and clinic-based investigations [65]. The present study also suffers from attrition
bias, losing participants with more severe eating disorders and/or depressive and anxiety symp-
tomatology during the follow-up period. The MoBa study has a low response rate (40.6% of all
women invited), with a possible self-selection of the healthiest women to the study. On the
other hand, among those who accepted the invitation, the response rate is high [26]. A previous
study [27] has thoroughly examined self-selection and its potential for bias by comparing the
MoBa study population with the total Norwegian birthing population, and concluded that
although the prevalence estimates could not necessarily be generalized, the measures of associ-
ations tested were valid in the MoBa study. We cannot, however, rule out that some of the asso-
ciation found here could be influenced by selection bias. Women excluded from the analysis
because of missing items for the eating disorder assessment had a more unfavorable profile
than the included counterpart, implying a plausible exclusion of women with more severe eat-
ing disorder symptoms. Our sample was small for the AN and EDNOS-P groups, limiting the
statistical power of most analyses. Information on medication dosage is not available in the
MoBa study and data about duration of exposure is not always adequate. Information about
type and timing of medication use is self-reported, thus dependent on the accuracy of the wom-
en’s reporting. However, the validity of self-reported use of antidepressants in the MoBa study
has been found to be reliable [63]. Information about ongoing psychological or psychothera-
peutic treatment for the various eating disorders was also not available in the MoBa study.
Symptoms of depression and anxiety were measured by two self-assessment instruments;
although such measurements cannot replace a clinical interview and are not designed to mea-
sure perinatal mood specifically, they provide a reliable measure of the severity of these psychi-
atric conditions [41,43]. Lastly, we cannot rule out the presence of unmeasured factors
confounding the association between eating disorders and medication use, and therefore can-
not conclude with regard to whether the associations found reflect causal relationships.
In view of our results, women with particularly low or high BMI should be queried about their
eating and medication-taking behaviors during the routine prenatal care check-ups. Pregnancy
represents an important window for recognition of psychiatric symptoms, including eating disor-
ders. During this phase of life, women with eating disorders may be motivated for treatment for
the well-being of the unborn child, and this could also prevent the recurrence of symptoms in the
post-partum period. Further studies are needed to explore whether women with eating disorders
self-medicate or receive prescriptions for gastrointestinal and analgesic medications during
pregnancy, as well as their medication-taking behavior in the later postpartum period. Future
studies should also evaluate the distinct effect of medicated and not medicated eating disorders
on immediate perinatal and long-term neurodevelopmental outcomes and should focus on how
obstetricians, psychiatrists, pharmacists, and midwives can formmultidisciplinary teams to
ensure that women with eating disorders in pregnancy receive the care and support they need for
themselves and their children during this important phase of life.
Conclusions
Our study indicated that psychotropics, especially antidepressants, are widely used by women
with eating disorders in the period before, during, and after pregnancy. In particular, women
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with AN or EDNOS-P were those most often taking psychotropics, which could partly be
related to the high psychiatric comorbidity. Women with BN were more likely than healthy
controls to initiate pharmacotherapy with psychotropics during pregnancy, even after account-
ing for the effect of indirect factors. Similarly, AN or EDNOS-P were directly associated with
use of anxiolytics/sedatives over the six month period after childbirth. While women with BED
were characterized by an extensive use of analgesics before, during and after pregnancy, use of
laxatives was high among women with any eating disorder at all time periods investigated.
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